Browsing Araştırma Çıktıları / Research Outputs by Subject "Polatuzumab vedotin"

Now showing items 1-2 of 2

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Dal, Mehmet Sinan; Ulu, Bahar Uncu; Uzay, Ant; Akay, Olga Meltem; Besisik, Sevgi; Yenerel, Mustafa Nuri; Celik, Serhat; Kaynar, Leylagul; Yucel, Orhan Kemal; Deveci, Burak; Sonmez, Mehmet; Mehtap, Ozgur (SPRINGER, )

Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had ...
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Dal, Mehmet Sinan; Ulu, Bahar Uncu; Uzay, Ant; Akay, Olga Meltem; Besisik, Sevgi; Yenerel, Mustafa Nuri; Celik, Serhat; Kaynar, Leylagul; Yucel, Orhan Kemal; Deveci, Burak; Sonmez, Mehmet; Mehtap, Ozgur (SPRINGER, 2023)

Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had ...